ANNA-BIOSCIENCES
22.6.2021 15:02:10 CEST | Business Wire | Press release
Anna Biosciences, a drug discovery company focused on novel therapies in immuno-oncology, virology, and neurodegenerative diseases, today announces its entry in the fight against COVID-19 with the introduction of its immunotherapy platform, Syntem.
The Anna Biosciences Syntem Platform deploys engineered proprietary molecules to create synthetic immunity. Syntem’s lab-made molecules are multi-specific: they first target and flag the pathology, and then elicit an immune reaction that targets the virus or disease.
Research indicates the Syntem Platform can inhibit viral infection and aid in the removal of COVID-19 infected cells. Showing promise as both a prophylactic and a treatment, there is considerable hope that in addition to supporting the broader population, immunocompromised patients will be able to safely use Syntem to prevent infection. Importantly, Syntem also exhibits high potential against COVID variants. In the case of COVID-19, and coronaviruses more generally, the Syntem Platform represents a significant new tool in the arsenal against these rapidly evolving diseases.
With today’s announcement, Anna Biosciences underscores both its initial successes in the lab and the successful patenting of the Syntem Platform. The company is now accelerating its commercialization effort to bring this potential COVID-19 treatment to market.
The Syntem Platform also shows strong promise for use against cancer and other pathogens. Research into the application of Syntem for oncological targets is currently underway. The resulting therapies could offer precision targeting, and the potential to mitigate side effects while being easier to administer to patients.
“Like vaccines in the 20th century, synthetic small molecule immunotherapy is on the precipice of advancing human health in untold ways. A powerful new tool is on the horizon in our fight against coronaviruses. And that’s just the beginning of this technology’s potential,” said Dr. Anthony Rullo, a scientific co-founder of Anna Biosciences and assistant professor of medicine at McMaster University in Ontario, Canada. “I’m extremely proud of our team, and the extraordinary effort of everyone involved at Anna Biosciences in the furthering of this technology.”
About Anna Biosciences
Anna Biosciences is a drug discovery company that uses decentralized partnerships to develop and advance new therapies for better patient outcomes. Anna Biosciences’ first initiative, the Syntem Platform, is developing proprietary molecules to trigger synthetic immunity for COVID-19 and beyond.
Anna Biosciences will continue to develop the Syntem Platform modality for additional therapies for a range of diseases. The company is currently working on the implementation of this approach to activate immune cells that can recognize and attack cancers.
For more information, visit http://annabiosciences.com/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210622005353/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sodali & Co Hires BlackRock Investment Stewardship AI and Data Lead11.2.2026 20:20:00 CET | Press release
Brett Miller to lead the firm’s global AI, data and insight offering Sodali & Co, the leading global capital markets-centric stakeholder advisory firm, is pleased to announce that Brett Miller has joined the firm as Global Head of Data Analytics based in New York. Miller joins from BlackRock where he served as Head of Data Analytics for its Investment Stewardship team. In his new role, Miller will lead Sodali’s global AI and data analytics strategy and embed data-driven insight across the firm’s integrated Shareholder Services, Sustainability, and Strategic Communications offering to help support clients navigate the increasingly complex and interconnected governance, investor, and stakeholder landscape. Miller joins Sodali & Co. at a time when investors are rapidly leveraging data and AI to drive investment and voting decisions. He will lead the buildout of an advanced analytics and technology platform to give clients actionable insight into how their narrative is driving capital flow
Andersen Consulting tilføjer Lighthouse Consultants11.2.2026 20:16:00 CET | Pressemeddelelse
Andersen Consulting indgår en samarbejdsaftale med Lighthouse Consultants, et London-baseret konsulentfirma med speciale i retsmedicinsk regnskab og finansielle undersøgelser. Lighthouse Consultants blev stiftet af administrerende direktør Kingsley Bye og leverer ydelser, der omfatter efterforskning af svindel og økonomisk kriminalitet, undersøgelser af bestikkelse og korruption, analyse af retssager og forsikringskrav, finansiel analyse, risikovurderinger, interne revisioner og compliance-gennemgange samt bæredygtighedsrevisioner. Virksomhedens team af erfarne statsautoriserede revisorer arbejder sammen med advokatfirmaer, formuende privatpersoner, virksomheder og velgørende organisationer med henblik på at løse komplekse tvister, mindske risici og øge gennemsigtigheden i finansielle og operationelle processer. "Ved at integrere vores retsmedicinske og efterforskningsmæssige ekspertise med Andersens globale platform kan vi levere en mere omfattende pakke af ydelser, der imødekommer ku
Egon Zehnder Opens Philadelphia Office to Support Leaders in the Region’s Fast-Growing Economy11.2.2026 15:00:00 CET | Press release
Firm establishes its 70th office worldwide, deepening its commitment to supporting clients in one of the nation’s premier leadership hubs Egon Zehnder, the world’s premier leadership advisory and executive search firm, today announced the opening of its Philadelphia office, marking the firm’s 70th office globally and further expanding its footprint in the United States. The new location strengthens Egon Zehnder’s long-standing commitment to serving clients across the Mid-Atlantic region with an integrated, advisory-led approach to leadership. Located in the FMC Tower, the Philadelphia office will deliver Egon Zehnder’s full suite of leadership advisory services and executive search to the region, including CEO succession, board effectiveness, executive search, leadership assessments, executive development, culture and organizational transformation and team effectiveness. The office will be staffed by consultants who live and work in the community, pairing global insights with local bus
Uniswap Labs and Securitize Collaborate to Unlock Liquidity Options for BlackRock’s BUIDL11.2.2026 15:00:00 CET | Press release
New integration pairs the efficiencies of Uniswap’s technology with the familiarity of traditional markets, enables near instant liquidity between BUIDL and USDC for investors Uniswap Labs, the leader in decentralized finance, and Securitize, the leader in tokenizing real-world assets (RWAs), today announced a strategic integration to make BlackRock USD Institutional Digital Liquidity Fund (BUIDL) shares available to trade via UniswapX technology. This integration will enable onchain trading of BUIDL, both unlocking new liquidity options for BUIDL holders, and marking a significant step in bridging the gap between traditional finance and DeFi. “Our mission at Labs is simple: make exchanging value cheaper, faster and more accessible,” said Hayden Adams, Uniswap Labs Founder and CEO. “Enabling BUIDL on UniswapX with BlackRock and Securitize supercharges our mission by creating efficient markets, better liquidity, and faster settlement. I’m excited to see what we build together.” Securiti
Calvin McDonald Joins The Wella Company as CEO11.2.2026 14:30:00 CET | Press release
--Industry Veteran with Track Record of Scaling Global Brands----Proven Leadership Driving Market Share and Profitable Growth-- The Wella Company, an innovative global beauty leader, today announced that Calvin McDonald has been chosen as the company’s next Chief Executive Officer, effective April 2, 2026. Calvin will also be appointed to the company’s Board of Directors and will be based in New York. Glenn Murphy will remain as Executive Chair to provide continuity as well as strategic advice to the new CEO and the leadership team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260210093439/en/ Calvin McDonald “We are delighted to welcome Calvin to The Wella Company,” said Glenn Murphy, Executive Chair. “As a three-time CEO, he brings decades of experience at industry-leading global consumer brands and retail businesses. Calvin’s proven ability to drive results through product differentiation, category expansion, and smart
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom